Patents by Inventor Kirston Koths

Kirston Koths has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized M-CSF specific monoclonal antibodies, kits, and uses thereof
    Patent number: 11034759
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: June 15, 2021
    Assignees: Novartis Vaccines and Diagnostics, Inc., Xoma Technology Ltd.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF
    Publication number: 20190263900
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: October 12, 2018
    Publication date: August 29, 2019
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF Specific Monoclonal Antibody and Uses Thereof
    Publication number: 20180171009
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: February 7, 2018
    Publication date: June 21, 2018
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF specific monoclonal antibody and uses thereof
    Patent number: 9926371
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: March 27, 2018
    Assignees: NOVARTIS VACCINES AND DIAGNOSTICS, INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF
    Publication number: 20170152311
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: November 9, 2016
    Publication date: June 1, 2017
    Applicants: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF specific monoclonal antibody and uses therof
    Patent number: 9522186
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: December 20, 2016
    Assignees: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEROF
    Publication number: 20160015809
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: June 3, 2015
    Publication date: January 21, 2016
    Applicants: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF specific monoclonal antibody and uses thereof
    Patent number: 9079956
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: July 14, 2015
    Assignees: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF
    Publication number: 20140242071
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: February 3, 2014
    Publication date: August 28, 2014
    Applicants: XOMA TECHNOLOGY LTD., NOVARTIS VACCINES AND DIAGNOSTICS INC.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • METHOD FOR PREVENTING AND TREATING CANCER METASTASIS AND BONE LOSS ASSOCIATED WITH CANCER METASTASIS
    Publication number: 20140093492
    Abstract: M-CSF antagonists are used to prepare compositions, including pharmaceutical compositions, for preventing or treating cancer metastasis and/or bone loss associated with cancer metastasis in a mammal.
    Type: Application
    Filed: March 25, 2013
    Publication date: April 3, 2014
    Applicant: NOVARTIS AG
    Inventors: Deborah Lee Zimmerman, Gregory Martin Harrowe, Cheng Liu, Kirston Koths, William Michael Kavanaugh
  • METHOD FOR PREVENTING AND TREATING CANCER METASTASIS AND BONE LOSS ASSOCIATED WITH CANCER METASTASIS
    Publication number: 20120045450
    Abstract: M-CSF antagonists are used to prepare compositions, including pharmaceutical compositions, for preventing or treating cancer metastasis and/or bone loss associated with cancer metastasis in a mammal.
    Type: Application
    Filed: August 23, 2011
    Publication date: February 23, 2012
    Applicant: NOVARTIS AG
    Inventors: William M. Kavanaugh, Gregory M. Harrowe, Kirston Koths, Cheng Liu, Deborah L. Zimmerman
  • Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
    Publication number: 20110091451
    Abstract: M-CSF antagonists are used to prepare compositions, including pharmaceutical compositions, for preventing or treating cancer metastasis and/or bone loss associated with cancer metastasis in a mammal.
    Type: Application
    Filed: August 9, 2004
    Publication date: April 21, 2011
    Inventors: William M. Kavanaugh, Gregory M. Harrowe, Kirston Koths, Cheng Liu, Deborah L. Zimmerman
  • M-csf specific monoclonal antibody and uses thereof
    Publication number: 20090324604
    Abstract: M-CSF-specific antibody RX1 is provided, along with pharmaceutical compositions containing antibody RX1, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: January 6, 2005
    Publication date: December 31, 2009
    Applicants: CHIRON CORPORATION, XOMA Technology Ltd.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory M. Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Arnold Horwitz, Maria Calderon-Cacia
  • Recombinant human CSF-1 dimer and compositions thereof
    Patent number: 6322779
    Abstract: The present invention is directed to an isolated and purified, recombinant, unglycosylated and dimeric CSF-1, the dimeric CSF-1 being biologically active and essentially endotoxin and pyrogen-free, the dimeric CSF-1 consisting essentially of two monomeric human CSF-1 subunits. The present invention is further directed to pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 27, 2001
    Assignee: Chiron Corporation
    Inventors: Robert Halenbeck, Kirston Koths, Cynthia Cowgill, Walter J. Laird
  • Soluble extracellular domain of human M-CSF receptor
    Patent number: 6184354
    Abstract: The present invention is directed to methods for crystallizing macrophage colony stimulating factor. The present invention is also directed to methods for designing and producing M-CSF agonists and antagonists using information derived from the crystallographic structure of M-CSF. The invention is also directed to methods for screening M-CSF agonists and antagonists. In addition, the present invention is directed to an isolated, purified, soluble and functional M-CSF receptor.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: February 6, 2001
    Assignee: Chiron Corporation
    Inventors: Kirston Koths, Eric Taylor
  • Identification of M-CSF agonists and antagonists
    Patent number: 6025146
    Abstract: The present invention is directed to methods for crystallizing macrophage colony stimulating factor. The present invention is also directed to methods for designing and producing M-CSF agonists and antagonists using information derived from the crystallographic structure of M-CSF. The invention is also directed to methods for screening M-CSF agonists and antagonists. In addition, the present invention is directed to an isolated, purified, soluble and functional M-CSF receptor.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: February 15, 2000
    Assignee: Chiron Corporation
    Inventors: Jayvardhan Pandit, Jarmila Jancarik, Sung-Hou Kim, Kirston Koths, Robert Halenbeck, Anna Lisa Fear, Eric Taylor, Ralph Yamamoto, Andrew Bohm
  • Crystallization of M-CSF.alpha.
    Patent number: 5866114
    Abstract: The present invention is directed to methods for crystallizing macrophage colony stimulating factor (M-CSF) and to a crystalline M-CSF produced thereby. The present invention is also directed to methods for designing and producing M-CSF agonists and antagonists using information derived from the crystallographic structure of M-CSF. The invention is also directed to methods for screening M-CSF agonists and antagonists. In addition, the present invention is directed to an isolated, purified, soluble and functional M-CSF receptor.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: February 2, 1999
    Assignee: Chiron Corporation
    Inventors: Jayvardhan Pandit, Jarmila Jancarik, Sung-Hou Kim, Kirston Koths, Robert Halenbeck, Anna Lisa Fear, Eric Taylor, Ralph Yamamoto, Andrew Bohm
  • Recombinant human CSF-1 dimer and compositions thereof
    Patent number: 5861150
    Abstract: The present invention is directed to a biologically active CSF-1 dimer comprising a first CSF-1 monomer and a second CSF-1 monomer, wherein at least one of the monomers is truncated at the C-terminus after residue position 223. The dimers also include point mutations in one or both of the CSF-1 monomer. The invention also includes pharmaceutical compositions that comprise the CSF-1 dimer in a pharmaceutical excipient.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 19, 1999
    Assignee: Chiron Corporation
    Inventors: Robert Halenbeck, Kirston Koths, Cynthia Cowgill, Walter J. Laird
  • Native type II GAP, methods for purifying various GAPs and uses of GAPs to diagnose cancer
    Patent number: 5830684
    Abstract: Native Type II GAP (GTPase activating protein), its uses in cancer diagnosis, and methods for obtaining and purifying native and recombinant Types I and II GAPs are described.
    Type: Grant
    Filed: December 7, 1990
    Date of Patent: November 3, 1998
    Assignee: Chiron Corporation
    Inventors: Robert Halenbeck, Kirston Koths, Francis P. McCormick, Bonnee Rubinfeld, Edward C. O'Rourke, Robin Clark, Gail L. Wong, George Martin
  • Heterodimers forms of CSF-1 and pharmaceutical compositions thereof
    Patent number: 5651963
    Abstract: The present invention relates to the production of CSF-1 heterodimers and pharmaceutical formulations of the heterodimers. The heterodimers can be formed using CSF-1 monomers that have variations in sequence, N or C-terminal processing. For example, CSF/C.gradient.150 can be dimerized with LCSF/C.gradient. 190 to form a heterodimer. Dimerization may occur by separately preparing homodimers and mixing them together under the appropriate conditions. Thereafter, homodimers may be separated from the heterodimers by various chromatographic techniques. Once the heterodimers are isolated, pharmaceutical preparations can be prepared.
    Type: Grant
    Filed: November 4, 1994
    Date of Patent: July 29, 1997
    Assignee: Chiron Corporation
    Inventors: Robert Halenbeck, Kirston Koths, Cynthia Cowgill, Walter J. Laird